Spine cancer combo therapy trial ends early after just one patient

This early-stage study tested combining targeted spine radiation with the immunotherapy drug pembrolizumab in people with advanced spinal tumors pressing on the spinal cord. Only one person enrolled before the study was stopped early. The goal was to see if this treatment approach was feasible and safe, but no conclusions can be drawn due to the very small number of participants.